{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MEK2+Gene+Mutation", "query": { "condition": "MEK2 Gene Mutation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T05:38:57.066Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04488003", "title": "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "BRAF Gene Mutation", "BRAF Gene Alteration", "MEK Mutation", "MEK Alteration", "MAP2K1 Gene Mutation", "MAP2K1 Gene Alteration", "MAP2K2 Gene Mutation", "MAP2K2 Gene Alteration" ], "interventions": [ { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Physician's Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioMed Valley Discoveries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2021-01-07", "completion_date": "2023-05-23", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-05-22T05:38:57.066Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04488003" }, { "nct_id": "NCT05054374", "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Cancer Stage IV", "HER2-negative Breast Cancer", "Solid Carcinoma", "MEK1 Gene Mutation", "MEK2 Gene Mutation", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-09-14", "completion_date": "2023-10-26", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-05-22T05:38:57.066Z", "location_count": 4, "location_summary": "Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more", "locations": [ { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05054374" }, { "nct_id": "NCT01933932", "title": "Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pegylated G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 510, "start_date": "2013-09-25", "completion_date": "2025-12-31", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-05-22T05:38:57.066Z", "location_count": 17, "location_summary": "Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01933932" }, { "nct_id": "NCT03434262", "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Ganglioglioma", "Anaplastic Meningioma", "Anaplastic Oligodendroglioma", "Pleomorphic Xanthoastrocytoma, Anaplastic", "Atypical Teratoid/Rhabdoid Tumor", "Brain Cancer", "Brain Tumor", "Central Nervous System Neoplasms", "Choroid Plexus Carcinoma", "CNS Embryonal Tumor With Rhabdoid Features", "Ganglioneuroblastoma of Central Nervous System", "CNS Tumor", "Embryonal Tumor of CNS", "Ependymoma", "Glioblastoma", "Glioma", "Glioma, Malignant", "Medulloblastoma", "Medulloblastoma; Unspecified Site", "Medulloepithelioma", "Neuroepithelial Tumor", "Neoplasms", "Neoplasms, Neuroepithelial", "Papillary Tumor of the Pineal Region (High-grade Only)", "Pediatric Brain Tumor", "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)", "Pineoblastoma", "Primitive Neuroectodermal Tumor", "Recurrent Medulloblastoma", "Refractory Brain Tumor", "Neuroblastoma. CNS", "Glioblastoma, IDH-mutant", "Glioblastoma, IDH-wildtype", "Medulloblastoma, Group 3", "Medulloblastoma, Group 4", "Glioma, High Grade", "Neuroepithelial Tumor, High Grade", "Medulloblastoma, SHH-activated and TP53 Mutant", "Medulloblastoma, SHH-activated and TP53 Wildtype", "Medulloblastoma, Chromosome 9q Loss", "Medulloblastoma, Non-WNT Non-SHH, NOS", "Medulloblastoma, Non-WNT/Non-SHH", "Medulloblastoma, PTCH1 Mutation", "Medulloblastoma, WNT-activated", "Ependymoma, Recurrent", "Glioma, Recurrent High Grade", "Glioma, Recurrent Malignant", "Embryonal Tumor, NOS", "Glioma, Diffuse Midline, H3K27M-mutant", "Embryonal Tumor With Multilayered Rosettes (ETMR)", "Ependymoma, NOS, WHO Grade III", "Ependymoma, NOS, WHO Grade II", "Medulloblastoma, G3/G4", "Ependymoma, RELA Fusion Positive" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" }, { "name": "sonidegib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 68, "start_date": "2018-03-05", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-05-31", "last_synced_at": "2026-05-22T05:38:57.066Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434262" }, { "nct_id": "NCT04534283", "title": "A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Cancer Metastatic", "BRAF V600E", "MEK1 Gene Mutation", "MEK2 Gene Mutation", "ERK Mutation", "RAF1 Gene Mutation" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "LY3214996", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anita Turk", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-10-05", "completion_date": "2023-08-07", "has_results": true, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-05-22T05:38:57.066Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04534283" } ] }